Mirakof® Tablet: Each sustained release tablet contains Butamirate Citrate INN 50 mg.
Mirakof® Syrup: Each 5 ml syrup contains Butamirate Citrate INN 7.5 mg.
Mirakof® (Butamirate Citrate) acts directly on the brain’s cough center to suppress cough. Mirakof® (Butamirate Citrate) is safe and non-sedating which is neither chemically nor pharmacologically related to opium alkaloids. Mirakof® is rapidly and completely absorbed after oral administration. Maximum concentration is reached within 9 hours with sustained release tablet. Mirakof® is extremely protein bound and plasma elimination half life is about 13 hours. The active metabolites of Mirakof® have also antitussive action.
Mirakof® (Butamirate Citrate) is used to relieve dry (non-productive) cough. Dry cough may be caused by a recent viral infection. Mirakof® (Butamirate Citrate) is also used for pre & post-operative cough sedation in patients who will undergo surgical procedures and bronchoscopy. It can be used in acute cough of any etiology, whooping cough and cough due to acute lower respiratory tract infections (tracheitis, laryngitis, bronchitis) etc.
Mirakof® Tablet: Adults: 2-3 tablets daily at 8 to 12 hours intervals. Adolescents over 12 years old: 1-2 tablets daily.
Mirakof® Syrup: Children (3-6 yrs) – 5 ml 3 times daily; Children (6-12 yrs) – 10 ml 3 times daily; Adolescent – 15 ml 3 times daily; Adults – 15 ml 4 times daily.
Butamirate Citrate should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution.
Keep away from light, store below 30°C. Keep all the medicines out of the reach of children.